Skip to content
Complete illustrative Retatrutide vial on travertine, with an unbranded Medically Tailored label.

INVESTIGATIONAL WEIGHT-LOSS SCIENCE

Retatrutide

Three pathways. Metabolic research. Clear expectations.

Retatrutide is an investigational peptide that activates GLP-1, GIP and glucagon receptors. Researchers are studying this three-pathway approach for weight loss and metabolic health. Clinical-trial findings do not make it an approved treatment or an available Body Alchemy Direct offering.

Retatrutide is not offered through Body Alchemy Direct. It is not FDA-approved, and FDA states that it cannot be used in compounding under federal law.

Triple-pathway science

Weight-loss research

Metabolic health

Body-composition research

A CLOSER LOOK

How Retatrutide Is Being Studied

GLP-1, GIP and glucagon receptor activity is being studied together. A 2023 phase 2 trial assessed weight change and adverse events over 48 weeks [1]; this remains research, not a Body Alchemy Direct treatment offer.

GLP-1

A pathway involved in appetite, fullness and glucose regulation. Researchers examine its contribution to the investigational medicine’s overall effects.

GIP

An incretin pathway involved in glucose-dependent insulin signaling. Its role is studied alongside GLP-1 and glucagon receptor activity.

Glucagon

A pathway involved in energy and glucose metabolism. Its contribution does not justify promises of muscle preservation or superior results.

CLINICAL RESEARCH FOCUS

  • Changes in body weight
  • Appetite and food-intake measures
  • Blood-glucose regulation
  • Metabolic-health markers
  • Body composition and fat distribution
  • Tolerability and longer-term outcomes

Clinical-trial outcomes depend on the studied population and protocol. They are not guaranteed personal results or claims for a compounded product.

READING THE TRIALS*

STUDY DESIGN

  • Identify the population
  • Review the comparator
  • Check study duration

RESULTS

  • Read average changes
  • Consider individual variation
  • Review adverse events

WHAT’S NEXT

  • Look for longer-term data
  • Follow regulatory updates
  • Compare approved options

* Trial follow-up periods are not a personal treatment schedule. No 1–12-week result promise or dosing plan is provided.

TOPICS TO DISCUSS

  • Medical weight-management goals
  • Appetite and metabolic concerns
  • Body-composition questions
  • Differences among GLP-1-related medicines
  • Currently available care options

YOUR QUESTIONS, ANSWERED

Frequently Asked Questions

View All FAQs →

How is retatrutide different?

It activates three receptor types—GLP-1, GIP and glucagon. This differs from single- or dual-receptor approaches, but does not by itself prove superiority or better tolerance.

What weight-loss results have been reported?

A 2023 phase 2 trial reported average weight reduction over 48 weeks, with results differing between study groups [1]. It does not predict an individual outcome or validate a compounded product.

How is it administered, and is it safe?

The published trial used a controlled injection protocol and reported gastrointestinal adverse effects. Trial supervision is not proof of routine-use safety; this guide provides no dosing instructions.

Can I receive retatrutide through Body Alchemy Direct?

No. It is investigational and is not offered here. FDA states that retatrutide cannot be used in compounding under federal law.

KNOW THE SCIENCE. UNDERSTAND THE LIMITS.

Understand the Next Chapter in Weight-Loss Research

Explore the science and learn how currently available care options are evaluated.

Explore the Library →

Explore the Science
Understand the Evidence
Ask Better Questions
Make Informed Choices

Research
Context

Evidence
Limits

Safety
Questions

Informed
Decisions

* Illustrative vial; not actual dispensed packaging. “Medically Tailored” is artwork wording and does not identify a verified formulation or promise treatment. Body Alchemy Direct does not manufacture, compound or dispense medication. This product is not offered; this page is educational only.